Furiex Pharmaceuticals, Inc. (NASDAQ:FURX)
| CAPS Rating |
|
|---|
FURX
VS S&P 500 (SPY)
FURX News and Commentary
- Furiex Enters Agreement For Priligy Product Rights – SmartMoney
- Underestimated Stocks: Hedge Funds Missed Out on These 9 Winning Streaks – The Motley Fool
- The 15 Most-Watched Life Sciences Stocks – The Motley Fool
- David Einhorn's Favorite Stock Picks, Better Returns Than S&P 500 – SeekingAlpha
- Healthcare Headlines: Santarus Rallies, Amgen Announces Results – SeekingAlpha
- David Einhorn's new Special Situation Stock – Blog at The Motley Fool
- Whale Watching: David Einhorn's Greenlight Capital – Blog at The Motley Fool
- Furiex Pharma's Cash Will Likely Run Out Before Investors Feel Secure – SeekingAlpha
How do you think FURX will perform against the market?
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
Powered by: CAPSAll Players
53
Outperform
2
Underperform
All-Star Players
7
Outperform
1
Underperform
Wall Street
3
Outperform
0
Underperform
RSS Headlines
Fool UK
